Abu Dhabi-based technology company G42 Healthcare has announced a volunteer healthcare management programme with Boston-based wearable technology firm WHOOP
The partnership will offer volunteers participating in the first phase III trials of an inactivated COVID-19 vaccine the opportunity to take advantage of a 24/7 fitness and health monitor to measure important biometrics. This is the first of its kind trial featuring wearable technology and will include thousands of volunteers taking part in the trials.
The Whoop4Humanity initiative ensures that volunteers who are now joining the ADNEC clinical trials in Abu Dhabi and the Al Qarain Centre in Sharjah, including those who are taking the second dose, can further enhance their participation in the trails by using new wearable devices to monitor their daily heart rate, respiratory rate, heart rate variability, sleep performance, and more.
G42 Healthcare CEO Ashish Koshy, said, “As a digital business, this new partnership is a logical extension of the highly-advanced AI and supercomputer solutions we are already using in the trials process. New volunteers will be invited to engage with the technology developed by WHOOP to enhance their individual volunteer experience and contribute to the advanced research involved in these sophisticated trials.
“We believe that allowing volunteers to use the WHOOP Strap 3.0 wearable device will reinforce their confidence in the trial by giving them the ability to check on several daily health data points. This will complement the world-class clinical expertise that the healthcare professionals in the UAE are providing to the volunteers and ensure their safety and well-being throughout the trials process.”
G42 Healthcare believes that WHOOP can be a powerful tool to boost the comprehensive voluntary healthcare management programme by helping thousands of vaccine volunteers to self-monitor their well-being while measuring their fitness, sleep, and recovery levels during the trials.
WHOOP provides valuable insights and actionable feedback around specific markers, thus encouraging better decision making for volunteers’ health and contributing to the trials’ overall success.
